Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CPA3 | P15088 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966557 | 0.89 | FOLH1 (0.55) | FOLH1CYP1A2KMT2A | |
| SCHEMBL12493936 | 0.87 | CYP1A2 (0.61) | FOLH1CYP1A2KMT2AATMCPA3 | |
| SCHEMBL1856103 | 0.87 | CA1 (0.51) | KMT2ATSHRSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL14294681 | 0.87 | HDAC3 (0.55) | FOLH1CYP1A2KMT2AATMALDH1A1 | |
| SCHEMBL27635862 | 0.85 | FOLH1 (0.51) | FOLH1CYP1A2KMT2AATMALDH1A1 | |
| SCHEMBL18065695 | 0.85 | EPHX2 (0.54) | CYP1A2KMT2ASMN1; SMN2CPA3LAP3 | |
| SCHEMBL1859677 | 0.85 | SMN1; SMN2 (0.50) | CYP1A2KMT2ATSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4845257 | 0.85 | KMT2A (0.49) | KMT2ATSHRSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL9555874 | 0.85 | KMT2A (0.53) | KMT2ATSHRSMN1; SMN2CPA3 | |
| SCHEMBL1859940 | 0.85 | GRIK1 (0.51) | FOLH1KMT2ATSHRSMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440051-B1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RES TRIANGLE INST (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-109153635-B | Neuropeptide S receptor (NPSR) agonists | 研究三角协会 | 2022-04-08 | — | — | CN | disclosed |
| US-11142546-B2 | Neuropeptide S receptor (NPSR) agonists | RESEARCH TRIANGLE INSTITUTE (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142546-B2 | Neuropeptide S receptor (NPSR) agonists | RESEARCH TRIANGLE INSTITUTE (US) | 2021-10-12 | — | — | US | disclosed |
| US-20190092809-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-28 | — | — | US | disclosed |
| US-20190092809-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-28 | — | — | US | disclosed |
| EP-3440051-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | Research Triangle Institute (US) | 2019-02-13 | — | — | EP | disclosed |
| CN-109153635-A | Neuropeptide S receptor (NPSR) agonist | 研究三角协会 | 2019-01-04 | — | — | CN | disclosed |
| WO-2017176461-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176461-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092809-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | NPSR1, GRPR, NPBWR1 | FOLH1 1267/4885CYP1A2 4100/4885KMT2A 2088/4885 |
| US-11142546-B2 | Neuropeptide S receptor (NPSR) agonists | NPSR1, GRPR, NPBWR1 | FOLH1 1267/4885CYP1A2 4100/4885KMT2A 2088/4885 |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | FOLH1 1635/4885CYP1A2 158/4885KMT2A 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.